Crown Laboratories Acquires Revance Therapeutics in $924M Merger
August 12, 2024
Crown Laboratories, Inc. entered into a merger agreement to acquire Revance Therapeutics, Inc. for $6.66 per share in cash, representing an enterprise value of $924 million. The deal closed after Crown commenced a tender offer and then completed a second-step merger, with Revance becoming wholly owned by Crown and delisted from Nasdaq.
- Buyers
- Crown Laboratories, Inc.
- Targets
- Revance Therapeutics, Inc.
- Industry
- Healthcare Services
- Location
- Tennessee, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.